PlumX Metrics
Embed PlumX Metrics

Long-Term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: A prospective, observational, multicenter study

Renal Replacement Therapy, ISSN: 2059-1381, Vol: 5, Issue: 1
2019
  • 2
    Citations
  • 0
    Usage
  • 12
    Captures
  • 0
    Mentions
  • 1
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    2
    • Citation Indexes
      2
  • Captures
    12
  • Social Media
    1
    • Shares, Likes & Comments
      1
      • Facebook
        1

Article Description

Background: This observational study investigated the safety and effectiveness of continuous erythropoietin receptor activator in patients with renal anemia in Japan. Methods: Patients were enrolled between August 2011 and November 2015 and followed for up to 1 year. Outcomes were analyzed according to disease stage (not receiving dialysis, on hemodialysis, on peritoneal dialysis). Results: Three thousand six hundred eighty-four patients were enrolled (1678 not receiving dialysis, 1605 on hemodialysis, 392 on peritoneal dialysis, and 9 other). Study treatment was well tolerated with no new safety concerns; adverse drug reactions were reported in 3.06%, 4.19%, and 4.46% of patients. Study treatment improved or maintained hemoglobin levels in 54.05-77.27% of patients, including erythropoiesis stimulating agent-naïve responders (hemoglobin ≥10.0 g/dL and hemoglobin increase ≥ 1.0 g/dL until week 24) and erythropoiesis-stimulating agent-switched responders (hemoglobin 10.0-12.0 g/dL at week 48). Conclusions: This study shows the safety and effectiveness of long-Term continuous erythropoietin receptor activator for renal anemia.

Bibliographic Details

Hidehiro Tabata; Hiroyuki Kanno; Ayako Murayama; Tadashi Ishii; Ryosuke Harada; Yukio Udagawa

Springer Science and Business Media LLC

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know